MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：17
|
作者：
Patel, V. [1 ]
Mansi, J. [2 ]
Ghosh, S. [2 ]
Kwok, J. [1 ]
Burke, M. [3 ]
Reilly, D. [3 ]
Nizarali, N. [3 ]
Sproat, C. [1 ]
Chia, K. [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Oral Surg, Fl 23,Tower Wing, London SE1 9RT, England
[2] Guys & St Thomas NHS Fdn Trust, Dept Oncol, Fl 23,Tower Wing, London SE1 9RT, England
[3] Guys & St Thomas NHS Fdn Trust, Sedat & Special Care, Fl 23,Tower Wing, London SE1 9RT, England
来源：
BRITISH DENTAL JOURNAL | 2018年 / 224卷 / 02期
关键词：
ZOLEDRONIC ACID; PREVENTIVE MEASURES; OSTEONECROSIS; JAW; IMPLEMENTATION; MANAGEMENT; REDUCE;
D O I：
10.1038/sj.bdj.2017.1039
中图分类号：
R78 [口腔科学];
学科分类号：
1003 ;
摘要：
Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.
引用
收藏
页码：74 / 79
页数：6
相关论文
共 50 条
  • [41] Oral bisphosphonates as adjuvant therapy for operable breast cancer
    Powles, Trevor
    McCroskey, Eugene
    Paterson, Alexander
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6301S - 6304S
  • [42] Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault, Richard L.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 61 - 66
  • [43] The role of bisphosphonates as adjuvant therapy for breast cancer.
    Gralow J.R.
    Current Oncology Reports, 2001, 3 (6) : 506 - 515
  • [44] The role of bisphosphonates in early breast cancer
    Paterson, Alexander H. G.
    ONCOLOGIST, 2006, 11 : 13 - 19
  • [45] Use of Bisphosphonates and Risk of Breast Cancer
    Peter Vestergaard
    Lone Fischer
    Marco Mele
    Leif Mosekilde
    Peer Christiansen
    Calcified Tissue International, 2011, 88 : 255 - 262
  • [46] Use of Bisphosphonates and Risk of Breast Cancer
    Vestergaard, Peter
    Fischer, Lone
    Mele, Marco
    Mosekilde, Leif
    Christiansen, Peer
    CALCIFIED TISSUE INTERNATIONAL, 2011, 88 (04) : 255 - 262
  • [47] Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
    Hadji, P.
    Coleman, R. E.
    Wilson, C.
    Powles, T. J.
    Clezardin, P.
    Aapro, M.
    Costa, L.
    Body, J. -J.
    Markopoulos, C.
    Santini, D.
    Diel, I.
    Di Leo, A.
    Cameron, D.
    Dodwell, D.
    Smith, I.
    Gnant, M.
    Gray, R.
    Harbeck, N.
    Thurlimann, B.
    Untch, M.
    Cortes, J.
    Martin, M.
    Albert, U. -S.
    Conte, P. -F.
    Ejlertsen, B.
    Bergh, J.
    Kaufmann, M.
    Holen, I.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 379 - 390
  • [48] THE RISK OF ISCHEMIC HEART DISEASE WITH ADJUVANT ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER
    Abdel-Qadir, H.
    Fischer, H.
    Fu, L.
    Amir, E.
    Harvey, P.
    Lee, D. S.
    Rochon, P.
    Anderson, G.
    CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (10) : S348 - S348
  • [49] Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer
    Albain, Kathy S.
    BREAST, 2011, 20 : S150 - S152
  • [50] Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer
    Lumachi, Franco
    Santeufemia, Davide A.
    Fadda, Giovanni M.
    Tozzoli, Renato
    Chiara, Giordano B.
    Basso, Stefano M. M.
    MEDICINAL CHEMISTRY, 2016, 12 (03) : 261 - 267
12345